On the detection of multiple-binding modes of ligands to proteins, from biological, structural, and modeling data

被引:40
作者
Lewis, PJ [1 ]
de Jonge, M
Daeyaert, F
Koymans, L
Vinkers, M
Heeres, J
Janssen, PAJ
Arnold, E
Das, K
Clark, AD
Hughes, SH
Boyer, PL
de Béthune, MP
Pauwels, R
Andries, K
Kukla, M
Ludovici, D
De Corte, B
Kavash, R
Ho, C
机构
[1] Janssen Pharmaceut NV, J&JPRD, Ctr Mol Design, Vosselaar, Belgium
[2] Rutgers State Univ, Ctr Biotechnol & Med, Piscataway, NJ 08855 USA
[3] Rutgers State Univ, Dept Chem & Biol Chem, Piscataway, NJ 08855 USA
[4] NCI, NIH, HIV Drug Resistance Program, Frederick, MD 21701 USA
[5] Tibotec Virco, Mechelen, Belgium
[6] Janssen Pharmaceut NV, J&JPRD, Dept Virol, Beerse, Belgium
[7] J&JPRD, Dept Chem, Spring House, PA USA
关键词
molecular modeling; virology; HIV; X-ray crystallography; drug design; statistical analysis; PLS;
D O I
10.1023/A:1025313705564
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
There are several indications that a given compound or a set of related compounds can bind in different modes to a specific binding site of a protein. This is especially evident from X-ray crystallographic structures of ligand-protein complexes. The availability of multiple binding modes of a ligand in a binding site may present an advantage in drug design when simultaneously optimizing several criteria. In the case of the design of anti-HIV compounds we observed that the more active compounds that are also resilient against mutation of the non-nucleoside binding site of HIV1-reverse transcriptase make use of more binding modes than the less active and resilient compounds.
引用
收藏
页码:129 / 134
页数:6
相关论文
共 16 条
[1]   STRUCTURAL-ANALYSIS OF A SERIES OF ANTIVIRAL AGENTS COMPLEXED WITH HUMAN RHINOVIRUS-14 [J].
BADGER, J ;
MINOR, I ;
KREMER, MJ ;
OLIVEIRA, MA ;
SMITH, TJ ;
GRIFFITH, JP ;
GUERIN, DMA ;
KRISHNASWAMY, S ;
LUO, M ;
ROSSMANN, MG ;
MCKINLAY, MA ;
DIANA, GD ;
DUTKO, FJ ;
FANCHER, M ;
RUECKERT, RR ;
HEINZ, BA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (10) :3304-3308
[2]   Crystal structures of 8-Cl and 9-Cl TIBO complexed with wild-type HIV-1 RT and 8-Cl TIBO complexed with the Tyr181Cys HIV-1 RT drug-resistant mutant [J].
Das, K ;
Ding, JP ;
Hsiou, Y ;
Clark, AD ;
Moereels, H ;
Koymans, L ;
Andries, K ;
Pauwels, R ;
Janssen, PAJ ;
Boyer, PL ;
Clark, P ;
Smith, RH ;
Smith, MBK ;
Michejda, CJ ;
Hughes, SH ;
Arnold, E .
JOURNAL OF MOLECULAR BIOLOGY, 1996, 264 (05) :1085-1100
[3]   STRUCTURE OF HIV-1 RT/TIBO R-86183 COMPLEX REVEALS SIMILARITY IN THE BINDING OF DIVERSE NONNUCLEOSIDE INHIBITORS [J].
DING, JP ;
DAS, K ;
MOEREELS, H ;
KOYMANS, L ;
ANDRIES, K ;
JANSSEN, PAJ ;
HUGHES, SH ;
ARNOLD, E .
NATURE STRUCTURAL BIOLOGY, 1995, 2 (05) :407-415
[4]   A distinct binding mode of a hydroxyethylamine isostere inhibitor of HIV-1 protease [J].
Dohnálek, J ;
Hasek, J ;
Dusková, J ;
Petroková, H ;
Hradilek, M ;
Soucek, M ;
Konvalinka, J ;
Brynda, J ;
Sedlácek, J ;
Fábry, M .
ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY, 2001, 57 :472-476
[5]  
Fischer E., 1894, Chem. Gesellschaft, V27, P2985, DOI DOI 10.1002/CBER.18940270364
[6]   CRYSTAL-STRUCTURE OF HUMAN-IMMUNODEFICIENCY-VIRUS TYPE-1 REVERSE-TRANSCRIPTASE COMPLEXED WITH DOUBLE-STRANDED DNA AT 3.0 ANGSTROM RESOLUTION SHOWS BENT DNA [J].
JACOBOMOLINA, A ;
DING, JP ;
NANNI, RG ;
CLARK, AD ;
LU, XD ;
TANTILLO, C ;
WILLIAMS, RL ;
KAMER, G ;
FERRIS, AL ;
CLARK, P ;
HIZI, A ;
HUGHES, SH ;
ARNOLD, E .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1993, 90 (13) :6320-6324
[7]   CRYSTAL-STRUCTURE AT 3.5 ANGSTROM RESOLUTION OF HIV-1 REVERSE-TRANSCRIPTASE COMPLEXED WITH AN INHIBITOR [J].
KOHLSTAEDT, LA ;
WANG, J ;
FRIEDMAN, JM ;
RICE, PA ;
STEITZ, TA .
SCIENCE, 1992, 256 (5065) :1783-1790
[8]   Evolution of anti-HIV drug candidates.: Part 1:: From α-anilinophenylacetamide (α-APA) to imidoyl thiourea (ITU) [J].
Ludovici, DW ;
Kukla, MJ ;
Grous, PG ;
Krishnan, S ;
Andries, K ;
de Béthune, MP ;
Azijn, H ;
Pauwels, R ;
De Clercq, E ;
Arnold, E ;
Janssen, PAJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (17) :2225-2228
[9]   Evolution of anti-HIV drug candidates part 2:: Diaryltriazine (DATA) analogues [J].
Ludovici, DW ;
Kavash, RW ;
Kukla, MJ ;
Ho, CY ;
Ye, H ;
De Corte, BL ;
Andries, K ;
de Béthune, MP ;
Azijn, H ;
Pauwels, R ;
Moereels, HEL ;
Heeres, J ;
Koymans, LMH ;
de Jonge, MR ;
Van Aken, KJA ;
Daeyaert, FFD ;
Lewi, PJ ;
Das, K ;
Arnold, E ;
Janssen, PAJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (17) :2229-2234
[10]   Evolution of anti-HIV drug candidates.: Part 3:: Diarylpyrimidine (DAPY) analogues [J].
Ludovici, DW ;
De Corte, BL ;
Kukla, MJ ;
Ye, H ;
Ho, CY ;
Lichtenstein, MA ;
Kavash, RW ;
Andries, K ;
de Béthune, MP ;
Azijn, H ;
Pauwels, R ;
Lewi, PJ ;
Heeres, J ;
Koymans, LMH ;
de Jonge, MR ;
Van Aken, KJA ;
Daeyaert, FFD ;
Das, K ;
Arnold, E ;
Janssen, PAJ .
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (17) :2235-2239